MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy

Johanna Heugenhauser; Malik Galijasevic; Stephanie Mangesius; Georg Goebel; Johanna Buchroithner; Friedrich Erhart; Josef Pichler; Georg Widhalm; Günther Stockhammer; Sarah Iglseder; Christian F. Freyschlag; Stefan Oberndorfer; Karin Bordihn; Gord von Campe; Thomas Czech; Birgit Surböck; Tadeja Urbanic Purkart; Christine Marosi; Thomas Felzmann; Martha Nowosielski

doi:10.3390/cancers14061579

MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy

Johanna Heugenhauser, Malik Galijasevic, Stephanie Mangesius^*, Georg Goebel, Johanna Buchroithner, Friedrich Erhart, Josef Pichler, Georg Widhalm, Günther Stockhammer, Sarah Iglseder, Christian F. Freyschlag, Stefan Oberndorfer, Karin Bordihn, Gord von Campe, Thomas Czech, Birgit Surböck, Tadeja Urbanic Purkart, Christine Marosi, Thomas Felzmann, Martha Nowosielski^*

^*Corresponding author for this work

Division of Neurology (University Hospital St. Pölten)

Research output: Journal article (peer-reviewed) › Journal article

8 Citations (Scopus)

Abstract

Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, n = 40) or SOC + Audencel vaccine (n = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each p < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.

Original language	English
Article number	1579
Journal	Cancers
Volume	14
Issue number	6
DOIs	https://doi.org/10.3390/cancers14061579
Publication status	Published - 20 Mar 2022

Keywords

Glioblastoma
Immunotherapy
IRANO
MRANO
Radiologic response criteria
Volumetric measurements

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers14061579

Cite this

Heugenhauser, J., Galijasevic, M., Mangesius, S., Goebel, G., Buchroithner, J., Erhart, F., Pichler, J., Widhalm, G., Stockhammer, G., Iglseder, S., Freyschlag, C. F., Oberndorfer, S., Bordihn, K., Campe, G. V., Czech, T., Surböck, B., Purkart, T. U., Marosi, C., Felzmann, T., & Nowosielski, M. (2022). MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. Cancers, 14(6), Article 1579. https://doi.org/10.3390/cancers14061579

@article{0ca8e98afeec4bb69a70b896b7be65d1,

title = "MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy",

abstract = "Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, n = 40) or SOC + Audencel vaccine (n = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each p < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.",

keywords = "Glioblastoma, Immunotherapy, IRANO, MRANO, Radiologic response criteria, Volumetric measurements",

author = "Johanna Heugenhauser and Malik Galijasevic and Stephanie Mangesius and Georg Goebel and Johanna Buchroithner and Friedrich Erhart and Josef Pichler and Georg Widhalm and G{\"u}nther Stockhammer and Sarah Iglseder and Freyschlag, {Christian F.} and Stefan Oberndorfer and Karin Bordihn and Campe, {Gord von} and Thomas Czech and Birgit Surb{\"o}ck and Purkart, {Tadeja Urbanic} and Christine Marosi and Thomas Felzmann and Martha Nowosielski",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

day = "20",

doi = "10.3390/cancers14061579",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

Heugenhauser, J, Galijasevic, M, Mangesius, S, Goebel, G, Buchroithner, J, Erhart, F, Pichler, J, Widhalm, G, Stockhammer, G, Iglseder, S, Freyschlag, CF, Oberndorfer, S, Bordihn, K, Campe, GV, Czech, T, Surböck, B, Purkart, TU, Marosi, C, Felzmann, T & Nowosielski, M 2022, 'MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy', Cancers, vol. 14, no. 6, 1579. https://doi.org/10.3390/cancers14061579

TY - JOUR

T1 - MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy

AU - Heugenhauser, Johanna

AU - Galijasevic, Malik

AU - Mangesius, Stephanie

AU - Goebel, Georg

AU - Buchroithner, Johanna

AU - Erhart, Friedrich

AU - Pichler, Josef

AU - Widhalm, Georg

AU - Stockhammer, Günther

AU - Iglseder, Sarah

AU - Freyschlag, Christian F.

AU - Oberndorfer, Stefan

AU - Bordihn, Karin

AU - Campe, Gord von

AU - Czech, Thomas

AU - Surböck, Birgit

AU - Purkart, Tadeja Urbanic

AU - Marosi, Christine

AU - Felzmann, Thomas

AU - Nowosielski, Martha

PY - 2022/3/20

Y1 - 2022/3/20

N2 - Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, n = 40) or SOC + Audencel vaccine (n = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each p < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.

AB - Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, n = 40) or SOC + Audencel vaccine (n = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each p < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.

KW - Glioblastoma

KW - Immunotherapy

KW - IRANO

KW - MRANO

KW - Radiologic response criteria

KW - Volumetric measurements

UR - http://www.scopus.com/inward/record.url?scp=85126564189&partnerID=8YFLogxK

U2 - 10.3390/cancers14061579

DO - 10.3390/cancers14061579

M3 - Journal article

C2 - 35326730

AN - SCOPUS:85126564189

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 6

M1 - 1579

ER -

MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this